Auriga to Host Investor Conference Call to Discuss Strategic Goals and Progress in Pharmaceutical Marketplace; Company CEO to Detail High-Growth Strategy Through Brand Acquisitions, New Drug Development and National Sales Operations.

NORCROSS, Ga. -- Auriga Laboratories(TM), Inc. (OTCBB:ARGA), a specialty pharmaceutical company committed to high-growth revenues through acquisition of valuable brand portfolios and innovative drug development programs, will host an investor conference call, with a simultaneous webcast, today, Wednesday, August 2, 2006, at 4:01 pm Eastern, to discuss recent Company events, progress and key strategic initiatives.

"We have made strong progress in our strategic business model to capitalize on significant revenue opportunities in the specialty pharmaceutical marketplace," said Philip S. Pesin, Chairman and Chief Executive Officer of Auriga Laboratories. "I look forward to updating investors about our key initiatives in building revenues through acquisitions, drug development and in our national sales operations."

Among Auriga's newest initiatives is the Company's recent implementation of an innovative plan to significantly expand its sales force through a cutting-edge commission-only structure designed to maximize revenues while minimizing costs. Auriga is among the first pharmaceutical companies to apply such an aggressive sales strategy.

Auriga's hybrid business model combines in-house drug development programs, product acquisitions and an experienced sales and marketing team. The Company is currently marketing or developing unique and proprietary drug solutions and delivery systems to treat a wide variety of major health conditions and ailments, including respiratory diseases, cold and allergies, gastrointestinal diseases and central nervous system disorders.

Interested investors can participate in the conference call by dialing 866-861-5393. When prompted tell the operator you would like to connect to the "Auriga conference call." International callers can 612-288-0337. An online audio web simulcast of the call will also be accessible at http://www.trilogy-capital.com/tcp/auriga/.

Auriga Laboratories(TM) Reincorporation and New Capitalization Information

Effective July 11, 2006, Multi-Link Telecommunications shareholders approved a 1-for-15 reverse split of its outstanding stock, (formerly OTCBB:MLNK) At the same time, Multi-Link reincorporated and merged into Auriga Laboratories, Inc., a Delaware corporation. By virtue of the merger, each outstanding post-split share of Multi-Link common stock was converted into the right to receive one share of Auriga common stock. Auriga is now traded on the Over-the-Counter Bulletin Board under the ticker symbol ARGA and has approximately 35.5M shares outstanding.

About Auriga Laboratories

Auriga Laboratories(TM) is a specialty pharmaceutical company capitalizing on high-revenue markets and opportunities in the pharmaceutical industry through aggressive sales, integrated marketing and advanced in-house drug development capabilities. The Company's high-growth business model combines acquisition of proven brand names, powerful product development strategies and rapidly-growing national sales teams and marketing operations. Auriga acquires valuable brand portfolios that are no longer a strategic focus for large pharmaceutical companies, then capitalizes on untapped marketplace opportunities through brand extension and directed sales/marketing programs. The Company's drug-development pipeline leverages novel material science and advanced drug delivery technologies to produce improved formulations of successful drug portfolio brands to further expand markets, sales and clinical indications for proven, successful products. Auriga's exclusive product portfolio currently includes the Extendryl(R) family of pharmaceutical products, indicated for treatment and relief of a range of acute respiratory diseases. Auriga plans to become a fully integrated pharmaceutical company by acquiring its own manufacturing and development capabilities. Moving forward, the Company will seek to acquire and/or in-license additional products and technologies to further grow revenues. For more information, please visit: www.aurigalabs.com. For investor-specific information and resources, visit http://www.trilogy-capital.com/tcp/auriga/. To read or download Auriga's Investor Fact Sheet, please visit http://www.trilogy-capital.com/tcp/auriga/factsheet.html. To view current stock quotes and news, visit http://www.trilogy-capital.com/tcp/auriga/quote.html.

Forward-Looking Statements 

The information contained herein includes forward-looking statements. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from our expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in our documents filed from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Statements regarding the regulatory status and/or regulatory compliance of our products, our ability to secure additional financing, our ability to sustain market acceptance for our products, our dependence on collaborators, our ability to find and execute strategic transactions, or potential exposure to litigation, our exposure to product liability claims, and our prices, future revenues and income and cash flows and other statements that are not historical facts contain predictions, estimates and other forward-looking statements. Although the Company believes that its expectations are based on reasonable assumptions, it can give no assurance that its goals will be achieved and these statements will prove to be accurate. Important factors could cause actual results to differ materially from those included in the forward-looking statements.